Xenoport Inc (XNPT.OQ)
XNPT.OQ on NASDAQ Stock Exchange Global Select Market
5.41USD
10:52am EDT
5.41USD
10:52am EDT
Price Change (% chg)
$0.02 (+0.37%)
$0.02 (+0.37%)
Prev Close
$5.39
$5.39
Open
$5.42
$5.42
Day's High
$5.54
$5.54
Day's Low
$5.39
$5.39
Volume
13,143
13,143
Avg. Vol
151,071
151,071
52-wk High
$12.98
$12.98
52-wk Low
$4.62
$4.62
About
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders. The product candidates are prodrugs that are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct... (more)
Overall
| Beta: | 0.51 |
| Market Cap (Mil.): | $255.50 |
| Shares Outstanding (Mil.): | 47.40 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| XNPT.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -1.02 | -- | -- |
| ROI: | -43.79 | -2.58 | 18.76 |
| ROE: | -51.01 | -2.66 | 19.59 |
XenoPort to drop multiple sclerosis drug, shares fall
- XenoPort Inc said it would stop development of an experimental multiple sclerosis treatment it planned to launch in 2015 after a late-stage trial failed to show significant improvement over a placebo.
UPDATE 2-XenoPort to drop multiple sclerosis drug after trial failure
* Drug does not show statistical significance compared with placebo
XenoPort to drop multiple sclerosis drug after trial failure
May 20 - XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo.
Competitors
| Price | Change | |
|---|---|---|
| GlaxoSmithKline plc (GSK.L) | 1,706.50p | +22.50 |
| Depomed Inc (DEPO.OQ) | $6.53 | +0.01 |
| Pfizer Inc. (PFE.N) | $29.18 | -0.05 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| UCB SA (UCB.BR) | €43.99 | +0.67 |
| NeurogesX, Inc (NGSX.PK) | $0.01 | +0.00 |
| Impax Laboratories Inc (IPXL.OQ) | $21.00 | +0.26 |
| Allergan, Inc. (AGN.N) | $91.71 | +0.59 |
| Sun Pharma Advanced Research Company (SPRC.NS) | Rs119.45 | -5.35 |
| Solvay S.A. (SOLB.BR) | €104.10 | +2.30 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

